Key result
Medical therapy with ARNI, alpha-blockers, and beta-blockers improves symptoms in VHL-associated dilated cardiomyopathy.
Why the study?
Von Hippel-Lindau syndrome presenting with congestive heart failure and dilated cardiomyopathy as the primary clinical manifestations has been rarely reported.
Case Report (n=1)
Dilated cardiomyopathy is a rare complication of Von Hippel-Lindau syndrome that can be managed with medical therapy including ARNI, beta-blockers, and alpha-blockers.
Answers are grounded in this paper and cite their sources.
Supports ARNI-inclusive therapy for rare VHL cardiomyopathy; hypothesis-generating and should not yet change practice.
BACKGROUND: Von Hippel-Lindau (VHL) syndrome is an autosomal dominant hereditary disease affecting multiple organs, with pheochromocytoma in 26% of cases. However, VHL syndrome with congestive heart failure and dilated cardiomyopathy as the primary clinical manifestations has been rarely reported. CASE PRESENTATION: A 35-year-old male patient was admitted to the hospital with dyspnea. The patient had a history of cerebellar hemangioblastoma that had been resected, and a one-year history of hypertension. Echocardiography and cardiac magnetic resonance imaging demonstrated a dilated left ventricle, decreased systolic function, and nonischemic myocardial changes. Contrast-enhanced abdominal computed tomography showed pheochromocytoma, neoplastic lesions, and multiple cysts in the kidneys and pancreas. Genetic analysis revealed a missense mutation of the VHL gene, c.269 A > T (p.Asn90Ile), which was identified as the cause of the disease. Dilated cardiomyopathy and VHL syndrome type 2 were diagnosed. The patient was administered a diuretic, α-blocker, β-blocker, and an angiotensin receptor neprilysin inhibitor (ARNI), but refused pheochromocytoma resection. At the six-month follow-up, the patient was asymptomatic with improved cardiac function. CONCLUSION: Cardiac involvement is an atypical manifestation in VHL syndrome. Early diagnosis with genetic screening is essential for avoiding life-threatening complications associated with VHL. The management of this rare manifestation of VHL syndrome requires further investigation.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2022) conducted a case report in Von Hippel-Lindau (VHL) syndrome with dilated cardiomyopathy (n=1). Medical therapy (diuretic, α-blocker, β-blocker, ARNI) was evaluated on Clinical symptoms and cardiac function. Medical management with an α-blocker, β-blocker, and ARNI improved symptoms and cardiac function in a 35-year-old male with rare dilated cardiomyopathy secondary to Von Hippel-Lindau syndrome who refused surgical resection.
Synapse has enriched 10 related papers. Consider them for comparative context: